This view is further supported by our study, where the prognostic value of MGMT methylation appears to go beyond a differential response to treatment between the methylated versus unmethylated tumours, to reflect a basic difference in the biology of these two variants of the tumour. This evidence concerns the gene MGMT and neoplasm.